Cancer Programs Critical For 'New AstraZeneca' As Price Pressure, Regulatory Changes Loom In 2017

CEO discussed oncology programs crucial to AstraZeneca’s future and was upbeat on US pricing pressure and Brexit as he insisted the company was "rapidly approaching a return to growth."